`
`
`
`Case 2:20-cv-00337-JRG Document 424 Filed 07/05/22 Page 1 of 2 PageID #: 16298
`
`UNITED STATES DISTRICT COURT
`EASTERN DISTRICT OF TEXAS
`MARSHALL DIVISION
`
`
` SEAGEN INC. DEFENDANTS' EXHIBIT LIST
`v.
`DAIICHI SANKYO CO., LTD.
`
`Case No. 2:20-cv-00337-JRG
`
`PRESIDING JUDGE:
`The Hon. Rodney Gilstrap
`
`PLAINTIFF'S ATTORNEYS: Michael
`A. Jacobs, Bryan Wilson, Matthew
`Chivvis, T. John Ward Jr., Jack Wesley
`Hill, Andrea Fair
`
`TRIAL DATES: June 28, 2022
`
`COURT REPORTER: Shawn
`McRoberts, RMR, CRR
`
`DEFENDANTS'
`ATTORNEYS: Deron R.
`Dacus, J. Mark Mann, G.
`Blake Thompson, Preston K.
`Ratliff II, Jeffrey A. Pade,
`Jennifer Parker Ainsworth,
`David Berl
`
`COURTROOM DEPUTY:
`Andrea Brunson
`
`
`
`PLF NO.
`DX-0006
`DX-0007
`DX-0008
`DX-0009
`DX-0010
`DX-0011
`
`DX-0012
`
`DX-0013
`DX-0014
`DX-0015
`DX-0016
`DX-0266
`
`DX-0282
`
`DX-0283
`
`DX-0285
`
`DX-0287
`
`
`
`DEF.
`NO.
`
`
`
`
`
`
`
`
`
`DATE
`OFFERED
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`
`MARKED
`
`
`
`
`
`
`
`
`
`
`
`ADMITTED
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`
`TRANSCRIPT
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6/28/22
`
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6/28/22
`
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`DESCRIPTION OF EXHIBITS
`File History of United States Patent No. 10,808,039
`File History of United States Patent No. 7,498,298
`File History of United States Patent No. 7,994,135
`File History of United States Patent No. 8,703,714
`File History of United States Patent No. 10,414,826
`File History of United States Patent Application No.
`14/194,106
`File History of United States Patent Application No.
`15/188,843
`United States Provisional Patent Application No. 60/518,534
`United States Provisional Patent Application No. 60/557,116
`United States Provisional Patent Application No. 60/598,899
`United States Provisional Patent Application No. 60/622,455
`Email from S. Jeffrey to P. Senter et al., dated March 9,
`2017
`Daiichi Sankyo Press Release, U.S. FDA Grants Fast Track
`Designation for HER2-Targeting Antibody Drug Conjugate
`DS-8201 for HER2-Positive Metastatic Breast Cancer, dated
`November 1, 2016
`Daiichi Sankyo Press Release, FDA Grants Breakthrough
`Therapy Designation to Daiichi Sankyo’s DS-8201 for
`HER2-Positive Metastatic Breast Cancer, dated August 29,
`2017
`Daiichi Sankyo Press Release, [Fam-] Trastuzumab
`Deruxtecan (DS-8201) Granted FDA Priority Review for
`Treatment of Patients with HER2 Positive Metastatic Breast
`Cancer, dated October 17, 2019
`Eric Palmer, Daiichi Sankyo to beef up ADC production with
`$135M investment in Japan, Fierce Pharma, dated April 27,
`2017
`
`- 2 -
`
`

`

`
`
`
`
`
`
`Case 2:20-cv-00337-JRG Document 424 Filed 07/05/22 Page 2 of 2 PageID #: 16299
`
`DX-0288
`DX-0289
`
`DX-0290
`DX-0293
`DX-0294
`
`DX-0295
`
`DX-0296
`DX-0297
`DX-0298
`
`DX-0416
`DX-0599
`
`DX-0600
`
`DX-1016
`
`DX-1055
`
`DX-1056
`
`DX-1057
`
`DX-1208
`
`DX-1209
`
`DX-1210
`
`DX-1211
`
`DX-1212
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6/28/22
`6/28/22
`
`6/28/22
`6/28/22
`6/28/22
`
`6/28/22
`
`6/28/22
`6/28/22
`6/28/22
`
`6/28/22
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6/28/22
`6/28/22
`
`6/28/22
`6/28/22
`6/28/22
`
`6/28/22
`
`6/28/22
`6/28/22
`6/28/22
`
`6/28/22
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`6/28/22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Chart re DS-8201
`Excel spreadsheet titled "ADC-Related Facilities
`Investment" and translation
`Excel spreadsheet and translation
`Email from N. Hernday to T. Held, dated July 31, 2018
`Email from K. Kitayama to N. Hernday, dated November
`10, 2018
`Non-Disclosure Agreement between Seattle Genetics, Inc.
`and Daiichi Sankyo Company, Ltd., dated October 10, 2018
`Seagen Draft V1 Term Sheet
`Seagen Draft Term Sheet, dated February 11, 2019
`Draft Clinical Study Protocol: A Phase 1, Multicenter,
`Open-label Study of Trastuzumab Deruxtecan (DS_8201a),
`an Anti-human Epidermal Growth Factor Receptor-2
`(HER2)-Antibody Drug Conjugate (ADC), in Combination
`with Tucatinib, a Tyrosine Kinase Inhibitor (TKI) for
`Subjects with HER2-Expressing Advances Breast Cancer
`Notes of Stephen Alley
`Presentation titled "Camptothecin panel screen", dated
`March 9, 2017
`Presentation titled "Camptothecin ADCs: Biological
`Evaluation", dated November 29, 2017
`Press Release, Daiichi Sankyo and AstraZeneca Announce
`Global Development and Commercialization Collaboration
`for Daiichi Sankyo’s HER2 Targeting Antibody Drug
`Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201),
`dated March 28, 2019
`Translation of Excel Spreadsheet
`DSC_ENHERTU_00388359
`Translation of Excel Spreadsheet
`DSC_ENHERTU_00388362
`Translation of Excel Spreadsheet
`DSC_ENHERTU_00388363
`United States Patent Application Publication No. US
`2019/0338045
`Expert Report of Mr. Robert Smith, dated November 13,
`2021
`Expert Report of Mr. David Manspeizer, dated November
`22, 2021
`Daiichi Sankyo Company, Limited’s Deposition Designation
`excerpts of the December 22, 2021 Deposition Transcript of
`Mr. Robert Smith
`Seagen Inc.’s Deposition Designation excerpts of the
`December 15, 2021 Deposition Transcript of Mr. David
`Manspeizer
`
`- 3 -
`
`